Who Owns Elder Pharmaceuticals Ltd. Company?

Elder Pharmaceuticals Ltd. Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Elder Pharmaceuticals Ltd.?

Unraveling the Elder Pharmaceuticals Ltd. SWOT Analysis reveals more than just market strategies; it highlights the crucial role of Company Ownership in shaping its destiny. Knowing who controls a Pharmaceutical Company like Elder Pharmaceuticals provides a window into its future, influencing everything from product development to market expansion. Understanding the Corporate Structure is key to grasping the company's trajectory.

The journey of Elder Pharmaceuticals, from its founding by Jagdish Saxena to its eventual restructuring, offers a compelling case study in the dynamics of ownership. The shifts in Shareholders and the impact of acquisitions, such as the deal with Torrent Pharmaceuticals, provide valuable lessons for investors and business strategists alike. This exploration will help you understand the Elder Group's evolution and answer questions like "Who is the owner of Elder Pharmaceuticals Ltd?" and "How to find Elder Pharmaceuticals Ltd. ownership details?".

The story of Elder Pharmaceuticals Ltd. began in 1989, founded by Jagdish Saxena in Mumbai. This marked the start of a new chapter for Saxena, who transitioned from his previous role to establish his own pharmaceutical venture. The company's initial manufacturing facility was set up in Nerul that same year, setting the stage for its future growth.

Jagdish Saxena, a first-generation entrepreneur, was the driving force behind the establishment of Elder Pharmaceuticals. While specific details about the initial equity distribution are not readily available, it's clear that Saxena's vision and leadership were crucial in the early stages. The company's evolution included strategic alliances and collaborations, expanding its network beyond its founders.

The company's transformation into a public limited company in August 1998 and its subsequent listing on the Bombay Stock Exchange and National Stock Exchange in 2000 were significant milestones. Early on, the company engaged in strategic alliances and collaborations, indicating a broader network of relationships beyond just the founders. For instance, in 2005, the Saxena family-controlled Elder Pharmaceuticals merged with its group company, Elder Projects.

Founding and Initial Ownership

Jagdish Saxena founded Elder Pharmaceuticals in 1989. He established the company after the closure of the pharmaceutical division of his previous employer. The initial focus was on building a strong pharmaceutical company.

Public Listing and Expansion

The company went public in 1998, listing on major stock exchanges in 2000. This move allowed for broader shareholder participation and access to capital.

Strategic Alliances

Elder Pharmaceuticals formed strategic alliances and collaborations early on. These partnerships were crucial for expanding its reach and capabilities. In 2005, the company merged with Elder Projects.

Early Investors

Early investors included Italy-based pharma firm Acraf SPA, which held approximately 10% equity in 2005. This indicates a mix of founder control and external investment.

Founder's Vision

The founding team, led by Jagdish Saxena, aimed to build a robust pharmaceutical company. The focus was on specific therapeutic areas and strategic growth.

Evolution of Ownership

The initial control rested with the founder, but the public listing and external investors broadened the shareholder base. This shift marked a significant change in the company's structure.

The early years of Elder Pharmaceuticals, a prominent Pharmaceutical Company, were defined by the vision of Jagdish Saxena. The company's transformation into a public entity and the introduction of shareholders like Acraf SPA broadened its structure. The maintained control while also incorporating external investment. The base expanded over time. The evolved from a founder-led entity to one with a more diverse ownership profile. This evolution is a key aspect of understanding the history of and its .

Elder Pharmaceuticals Ltd. SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Elder Pharmaceuticals Ltd., a pharmaceutical company, has seen significant shifts since its public listing in 2000. The most impactful change occurred on December 13, 2013, when Torrent Pharmaceuticals Limited acquired Elder's branded domestic formulations business in India and Nepal for approximately ₹2,000 crore. This transaction included a portfolio of 30 brands and the transfer of employees, fundamentally altering Elder Pharmaceuticals' operational scope. Understanding the history of ownership provides context for the current status of the company.

Following the sale to Torrent, Elder Pharmaceuticals faced continued financial difficulties, leading to its delisting from the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in 2016 due to non-compliance. As of June 14, 2024, the company is 'Under Liquidation'. The Elder Group's corporate structure has been significantly impacted by these events, changing the focus from shareholders to creditors and the liquidator in the distribution of any remaining assets.

Before delisting, the promoter group was led by Anuj Saxena and Shalini Saxena Kumar, with Alok Saxena as Managing Director and CEO. In 2015, internal family disputes over Jagdish Saxena's assets were reported. At that time, Semit Pharmaceuticals and Chemicals and Indarts Exports held 7.55% and 7.70% respectively in Elder Pharma. The Securities and Exchange Board of India (SEBI) rejected a proposed shareholding recast plan by the promoters in 2015. For more details, you can read this article about Elder Pharmaceuticals Ltd.

Current Ownership Structure of Elder Pharmaceuticals

The current ownership structure of Elder Pharmaceuticals is defined by its liquidation status. The focus has shifted from shareholders to creditors. The liquidator manages the distribution of any remaining assets.

• The company is currently 'Under Liquidation' as of June 14, 2024.
• The primary stakeholders are now creditors and the appointed liquidator.
• Shareholders' interests are secondary to the liquidation process.
• The history of ownership includes key events like the sale to Torrent and delisting.

Elder Pharmaceuticals Ltd. PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of June 14, 2024, Elder Pharmaceuticals Limited is listed as 'Under Liquidation'. This status significantly impacts the board of directors' role and shareholder voting power. The primary responsibility shifts to a liquidator, who manages the company's assets to settle debts and distribute funds according to legal priorities. Understanding the Company Ownership in this context requires acknowledging the shift from operational governance to liquidation proceedings.

Prior to liquidation, the board of directors included individuals like Alok Saxena, who served as Managing Director and CEO in 2013. Other directors listed as of June 17, 2024, were Abdul Khader Mohammed Ravani, Vijendra Kumar Jain, and Kader Mohamed Davawala. These individuals comprised the board before the company entered liquidation. The Elder Group's corporate structure and the roles of these key personnel are essential for understanding the company's trajectory.

Historically, Shareholders exercised voting rights based on their share of the paid-up capital. However, the company's financial struggles, including non-compliance with listing agreements and significant debt, severely impacted the board's decision-making and the value of shareholder voting power. For more details on the company's background, see Brief History of Elder Pharmaceuticals Ltd.

Ownership Dynamics in Liquidation

In liquidation, the liquidator manages assets, and the board's role diminishes. Shareholder voting power is subject to the liquidation process and debt repayment priorities. The focus shifts from operational governance to the distribution of remaining assets to creditors and shareholders.

• Liquidation status impacts board and shareholder roles.
• Liquidator manages assets for debt settlement.
• Shareholder voting rights are subject to liquidation outcomes.
• Financial distress significantly affected governance.

Elder Pharmaceuticals Ltd. Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The most significant recent development regarding Elder Pharmaceuticals is its 'Under Liquidation' status as of June 14, 2024. This marks a critical shift in the company's ownership profile. The company's history includes the sale of its branded domestic formulations business to Torrent Pharmaceuticals in December 2013 for ₹2,000 crore, which, however, did not prevent subsequent financial difficulties.

The company was delisted from the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in 2016 due to non-compliances. This delisting changed its structure from a publicly traded entity to a privately held one. The founder, Jagdish Saxena, passed away in October 2013. His son, Alok Saxena, who was the Managing Director and CEO, passed away in October 2017. Following this, Anuj Saxena and Shalini Saxena Kumar, the founder's children, led the promoter group. The focus now is on resolving financial obligations under the supervision of a liquidator. Understanding the Growth Strategy of Elder Pharmaceuticals Ltd. provides additional context to its challenges.

In its current state, Elder Pharmaceuticals is not subject to industry trends such as increased institutional ownership. The company's financial struggles, including poor sales growth and low return on equity, and significant contingent liabilities, reflect the challenges it faced leading up to its liquidation. As of 2024, the ownership structure is primarily dictated by the liquidation process, not by active investment or market activities.

Key Developments

The company is currently under liquidation as of June 14, 2024. The delisting from stock exchanges in 2016 marked a significant change in ownership. The focus is on resolving financial obligations under the supervision of a liquidator.

Ownership Changes

Following the founder's passing, the promoter group was led by Anuj Saxena and Shalini Saxena Kumar. The liquidation process now determines the company's ownership dynamics. Financial challenges led to these significant shifts in the corporate structure.

Financial Troubles

The sale of the branded domestic formulations business did not prevent financial difficulties. Poor sales growth and low return on equity contributed to the company's challenges. Significant contingent liabilities further impacted the company's standing.

Current Status

Elder Pharmaceuticals is no longer a publicly traded company. The ownership structure is dictated by the liquidation process. Industry trends in ownership structure are not applicable in its current state.

Elder Pharmaceuticals Ltd. Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs